Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.01
STEM's Cash to Debt is ranked higher than
60% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. STEM: 2.01 )
STEM' s 10-Year Cash to Debt Range
Min: 0.66   Max: 63.74
Current: 2.01

0.66
63.74
Equity to Asset 0.37
STEM's Equity to Asset is ranked higher than
57% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. STEM: 0.37 )
STEM' s 10-Year Equity to Asset Range
Min: -0.09   Max: 0.83
Current: 0.37

-0.09
0.83
F-Score: 2
Z-Score: -13.43
M-Score: -3.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -2662.54
STEM's Operating margin (%) is ranked higher than
54% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. STEM: -2662.54 )
STEM' s 10-Year Operating margin (%) Range
Min: -50159.65   Max: -63.56
Current: -2662.54

-50159.65
-63.56
Net-margin (%) -2530.41
STEM's Net-margin (%) is ranked higher than
54% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. STEM: -2530.41 )
STEM' s 10-Year Net-margin (%) Range
Min: -43900   Max: -75.42
Current: -2530.41

-43900
-75.42
ROE (%) -374.02
STEM's ROE (%) is ranked higher than
50% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. STEM: -374.02 )
STEM' s 10-Year ROE (%) Range
Min: -230.6   Max: -19.04
Current: -374.02

-230.6
-19.04
ROA (%) -80.99
STEM's ROA (%) is ranked higher than
56% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. STEM: -80.99 )
STEM' s 10-Year ROA (%) Range
Min: -102.9   Max: -13.62
Current: -80.99

-102.9
-13.62
ROC (Joel Greenblatt) (%) -589.52
STEM's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. STEM: -589.52 )
STEM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1314.64   Max: -38.27
Current: -589.52

-1314.64
-38.27
Revenue Growth (3Y)(%) -37.00
STEM's Revenue Growth (3Y)(%) is ranked higher than
63% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. STEM: -37.00 )
STEM' s 10-Year Revenue Growth (3Y)(%) Range
Min: -81.5   Max: 128.9
Current: -37

-81.5
128.9
EBITDA Growth (3Y)(%) -33.70
STEM's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. STEM: -33.70 )
STEM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -33.7   Max: 9.6
Current: -33.7

-33.7
9.6
EPS Growth (3Y)(%) -33.20
STEM's EPS Growth (3Y)(%) is ranked higher than
62% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. STEM: -33.20 )
STEM' s 10-Year EPS Growth (3Y)(%) Range
Min: -33.2   Max: 24.1
Current: -33.2

-33.2
24.1
» STEM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2012

STEM Guru Trades in Q3 2012

Jim Simons 536,200 sh (-26.46%)
» More
Q4 2012

STEM Guru Trades in Q4 2012

Jim Simons 24,300 sh (-95.47%)
» More
Q1 2013

STEM Guru Trades in Q1 2013

Jim Simons Sold Out
» More
Q3 2014

STEM Guru Trades in Q3 2014

Jim Simons 60,633 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with STEM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.00
STEM's P/B is ranked higher than
79% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. STEM: 4.00 )
STEM' s 10-Year P/B Range
Min: 1.12   Max: 22
Current: 4

1.12
22
P/S 46.00
STEM's P/S is ranked higher than
71% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. STEM: 46.00 )
STEM' s 10-Year P/S Range
Min: 6.61   Max: 3320
Current: 46

6.61
3320
EV-to-EBIT -1.52
STEM's EV-to-EBIT is ranked lower than
55% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. STEM: -1.52 )
STEM' s 10-Year EV-to-EBIT Range
Min: -20.5   Max: 0.1
Current: -1.52

-20.5
0.1
Current Ratio 4.27
STEM's Current Ratio is ranked higher than
71% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. STEM: 4.27 )
STEM' s 10-Year Current Ratio Range
Min: 1.75   Max: 21.05
Current: 4.27

1.75
21.05
Quick Ratio 4.27
STEM's Quick Ratio is ranked higher than
72% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. STEM: 4.27 )
STEM' s 10-Year Quick Ratio Range
Min: 1.75   Max: 21.05
Current: 4.27

1.75
21.05

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.50
STEM's Price/Net Cash is ranked higher than
81% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. STEM: 11.50 )
STEM' s 10-Year Price/Net Cash Range
Min: 3.34   Max: 139.82
Current: 11.5

3.34
139.82
Price/Net Current Asset Value 11.50
STEM's Price/Net Current Asset Value is ranked higher than
80% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. STEM: 11.50 )
STEM' s 10-Year Price/Net Current Asset Value Range
Min: 3.32   Max: 97.01
Current: 11.5

3.32
97.01
Price/Tangible Book 5.10
STEM's Price/Tangible Book is ranked higher than
80% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. STEM: 5.10 )
STEM' s 10-Year Price/Tangible Book Range
Min: 0.85   Max: 23.75
Current: 5.1

0.85
23.75
Price/Median PS Value 0.20
STEM's Price/Median PS Value is ranked higher than
98% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. STEM: 0.20 )
STEM' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 12.05
Current: 0.2

0.01
12.05
Earnings Yield (Greenblatt) -65.80
STEM's Earnings Yield (Greenblatt) is ranked higher than
50% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. STEM: -65.80 )
STEM' s 10-Year Earnings Yield (Greenblatt) Range
Min: -65.8   Max: 54835.9
Current: -65.8

-65.8
54835.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CY9A.Germany,
StemCells, Inc. is a Delaware Corporation incorporated in 1988. The Company is engaged in the research, development, and commercialization of stem cell therapeutics and related enabling technologies for academia and industry. It is focused on cellular medicine, or the use of stem and progenitor cells as the basis for novel therapeutics and therapies, and enabling technologies for stem cell research, or the use of cells and related technologies to enable stem cell-based research and drug discovery and development. The Company's primary research and development efforts are focused on cellular medicine, where it seeks to identify and develop stem and progenitor cells as potential therapeutic agents. It currently has two therapeutic product development programs; its CNS Program, which is developing applications for HuCNS-SC cells, its proprietary human neural stem cell product candidate, and its Liver Program, which is developing applications for its proprietary human liver engrafting cells. It currently markets various proprietary cell culture products under the SC Proven brand, including iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27. The Company's primary strategy is to identify multiple types of human stem and progenitor cells with therapeutic and commercial importance, to develop techniques and processes to purify these cells for direct transplant and to expand and bank these cells, to advance these cells into clinical development and ultimately, to commercialize them as cell-based therapeutic products. The Company's research and development activities and the future manufacturing and marketing of its potential therapeutic products are, and would continue to be, subject to regulation for safety and efficacy by numerous governmental authorities in the United States and other countries.
» More Articles for STEM

Headlines

Articles On GuruFocus.com
Billionaires Hold Waning Biotechs 42% Off Oct 16 2013 
comment on STEM Feb 09 2012 
Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
StemCells Inc. Reports Operating Results (10-Q) Nov 03 2010 
StemCells Inc. Reports Operating Results (10-Q) May 04 2010 
StemCells Inc. Reports Operating Results (10-Q) Nov 05 2009 
StemCells, Inc. Reports Second Quarter Financial Results Aug 10 2009 
StemCells Inc. Reports Operating Results (10-Q) Aug 10 2009 
The Next Boom Emerges Nov 23 2008 

More From Other Websites
REUTERS AMERICA NEWS PLAN FOR THURSDAY DEC 18 Dec 18 2014
StemCells, Inc. Transplants First Participant in Phase II Clinical Trial in Cervical Spinal Cord... Dec 18 2014
StemCells, Inc. Transplants First Participant in Phase II Clinical Trial in Cervical Spinal Cord... Dec 18 2014
STEMCELLS INC Files SEC form 8-K, Termination of a Material Definitive Agreement Dec 12 2014
StemCells, Inc. Hosts Leading Biotech Investors and Analysts at Inaugural Event Dec 02 2014
StemCells, Inc. Hosts Leading Biotech Investors and Analysts at Inaugural Event Dec 02 2014
STEMCELLS INC Financials Nov 21 2014
StemCells, Inc. to Host Inaugural Investor and Analyst Event in New York Nov 20 2014
StemCells, Inc. to Host Inaugural Investor and Analyst Event in New York Nov 20 2014
10-Q for StemCells, Inc. Nov 15 2014
STEMCELLS INC Files SEC form 10-Q, Quarterly Report Nov 13 2014
STEMCELLS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 06 2014
StemCells, Inc. Reports Third Quarter 2014 Financial and Operating Results Nov 05 2014
StemCells, Inc. Reports Third Quarter 2014 Financial and Operating Results Nov 05 2014
StemCells, Inc. to Host Inaugural Investor and Analyst Event in New York Nov 03 2014
StemCells, Inc. to Host Inaugural Investor and Analyst Event in New York Nov 03 2014
StemCells Starts Phase II Cervical Spinal Cord Injury Study Oct 08 2014
STEMCELLS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 08 2014
StemCells, Inc. Initiates Phase II Clinical Trial in Cervical Spinal Cord Injury Oct 07 2014
StemCells, Inc. to Participate at the 2014 Stem Cell Meeting on the Mesa Oct 01 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK